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Psychological therapy 
Randomised controlled trial 
A B S T R A C T   
Background: Around half of people diagnosed with schizophrenia suffer from co-morbid depression, yet there are 
no evidence-based psychological treatments to target this presentation. 
Method: Participants were aged 18–65 years old, had a clinical diagnosis of schizophrenia or schizoaffective 
disorder and at least a mild level of depression. Participants were randomly assigned (1:1) to receive PoMeT or 
treatment as usual. PoMeT was delivered in up to 12 individual sessions within 3 months. We stratified ran-
domisation by site and by severity of depression using randomised-permuted blocks. Assessments were carried 
out at baseline, 3-month, 6-month and 9-month by assessors who were blind to treatment allocation. The pri-
mary outcome was reduction in the symptoms of depression at 3-month, 6-month and 9-month as measured by 
the BDI-II. Analysis was by intention-to-treat with linear mixed-effects models. The trial was registered with the 
ISRCTN registry number 99485756. 
Results: One hundred participants were randomly assigned to either PoMeT (n = 49) or treatment as usual 
(n = 51). The reduction in BDI-II total score at 3 months was significantly greater for PoMeT than for treatment 
as usual (mean difference = 4.33, SE = 2.00, 95% CI 0.38 to 8.23; p = 0.03). 
Discussion: To our knowledge this is, to date, the largest powered randomised controlled trial focused on the 
psychological treatment of depression in people diagnosed with schizophrenia. Results indicate that a brief 
targeted intervention can reduce the symptoms of depression in the group. The main limitation of the study is the 
lack of an active control group which may contribute to an inflated treatment effect.   
1. Introduction 
Schizophrenia incurs an estimated treatment cost of £2 billion per 
annum within the UK alone (Mangalore & Knapp, 2007). The devel-
opment of cost-effective interventions is therefore a priority. Previous 
research has culminated in the current UK government guidelines re-
commending 16 individual sessions of cognitive-behaviour therapy 
(CBT) over a period of 6 months (NICE, 2009). The protocols used 
within CBT for schizophrenia have typically been generic and flexible, 
so that clinicians can treat the wide range of presenting problems as-
sociated with a psychotic disorder. CBT for schizophrenia, therefore, 
currently requires a prolonged period of training for clinicians, which 
has contributed to a low level of availability (Haddock et al., 2014). 
Consequently, recent efforts have been focussed on the development of 
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brief manualised psychological interventions for psychosis which re-
quire less training and delivery time. Typically, these interventions 
target a specific psychotic symptom, such as paranoia (Freeman et al., 
2015) or a specific co-morbid presentation, such as post-traumatic 
stress disorder (Steel et al., 2017; van den Berg et al., 2015). 
Low mood is highly prevalent within people diagnosed with schi-
zophrenia, with an estimated 50% suffering from a diagnostic level of 
depression (Buckley, Miller, Lehrer, & Castle, 2009). This co-morbid 
condition is associated with particularly high levels of health care use, 
and a suicide rate of 5% (Palmer, Pankratz, & Bostwick, 2005). The 
effectiveness of anti-depressants is small for this group (Helfer, Samara, 
Huhm, Klupp, Leucht, Zhu et al., 2016). 
The evidence base for the psychological treatment of depression 
originates from clinical trials which have excluded people who present 
with a psychotic disorder. To date, most reports of a psychological 
approach to treating depression in schizophrenia have been small pilot 
and feasibility studies (e.g. Gaudiano et al., 2015; Gumley et al., 2017;  
Singer, Addington, Bobson, & Wright, 2014). Opoka and Lincoln's 
(2017) review of the area includes five trials, and concludes that cog-
nitive behavioural interventions can successfully treat co-morbid de-
pression in this group. However, only one study (Freeman et al., 2014) 
included both a control group and follow-up. The intervention was brief 
(6-sessions), targeted, and associated with a significant decrease in the 
secondary outcomes of depression and self-esteem which were not 
maintained during the follow-up phase. A more recent study evaluated 
6-months of generic CBT targeting depression and self-esteem in a 
sample of 63 participants from an early psychosis population (Sonmez, 
Romm, Ostefjells, Grande, Jensen, Hummelen et al., 2020) and did not 
show a significant effect of the intervention. 
Psychological models of psychosis suggest that negative affect has a 
central role in the development and maintenance of positive symptoms 
(Garety et al., 2001). It is therefore likely that a significant change in 
mood will result in a subsequent change in psychotic symptoms severity 
within people diagnosed with schizophrenia. This latter point is sup-
ported by a recent review specifically with respect to delusions (Opoka, 
Ludwig, & Lincoln, 2018). Low mood, therefore, represents an im-
portant but relatively neglected treatment target in this group. Further, 
low mood is likely to be maintained through negative self-concepts, and 
low levels of self-esteem, which have also been found to be prevalent 
within people diagnosed with a psychotic disorder (Smith, Fowler, 
Freeman, Bebbington, Bashforth, Garety., et al., 2006). Change in mood 
is therefore likely to be mediated through a change in self-esteem. 
The current study aimed to evaluate the effect of a short-term 
psychological intervention, which specifically targets the cognitive 
processes associated with mood disorder, for people diagnosed with 
schizophrenia. 
1.1. Development of the current intervention 
A recently developed evidence based treatment for depression and 
self-esteem is termed ‘competitive memory training’ (CoMeT) (Ekkers, 
Korrelboom, Huijbrects, Smits, Cuijpefrs & van der Gaag, 2011;  
Korrelboom, de Jong, Huirbrechts, & Daansen, 2009; Korrelboom, 
Marissen, & van Assendelft, 2011; Korrelboom, Marrisen & Huijbrechts, 
2012; Korrelboom, van der Weele, Gjaltema, & Hoogstraten, 2009). The 
name is based on the theory that we all have access to a number of 
different self-representations, each of which is associated with person-
ally relevant memories (Brewin, 2006). Any of these representations 
may be activated within a certain situation, thus, the element of 
‘competition’. It is argued that individuals with depression suffer from 
negative self-representations which are easily triggered by a wide range 
of stimuli, along with the associated experience of negative memories 
and low mood. During the CoMeT intervention, patients are trained to 
enhance the activation of a positive self-representation using a variety 
of experiential techniques. Latter stages of the protocol involve acti-
vating their positive self-representation during the kind of stressful 
experiences which had previously triggered negative self-representa-
tions. Hence, the positive representations are given a competitive 
‘edge’. 
The training element of the intervention is comparable to the ap-
proach taken within cognitive remediation programmes for schizo-
phrenia, which has been shown to be effective (Wykes, Huddy, Cellard, 
McGurk, & Czobor, 2011). The use of a training-based method which 
employs imagery and experiential techniques means that the inter-
vention does not require the patient to have high levels of ‘executive’ 
skills (e.g. planning, memory and attention), which are often reduced 
within the patient group (Fioravanti, Carlone, Vitale, Cinti, & Clare, 
2005). The advantages of using CoMeT over standard CBT for schizo-
phrenia therefore include (i) it specifically targets a key psychological 
process in the maintenance of depression and (ii) the manualised pro-
tocol requires a lower level of therapist training in order to achieve 
adherence. CoMeT is also shorter in duration (3 months) than other 
evidence-based treatments for depression, such as Beckian CBT (Butler, 
Chapman, Forman, & Beck, 2006), behavioural activation (Jacobsen, 
Martell & Dimidjan, 2001) and mindfulness (Kuyken et al., 2008). 
Clinical trials indicate that CoMeT is effective for the treatment of mood 
problems within a range mental health conditions, including eating 
disorders and personality disorders (Ekkers et al., 2011; Korrelboom 
et al., 2009a, 2009b, 2011, 2012). Also, an adapted form of CoMeT has 
been used in a study which targeted the treatment of depression within 
people who experienced distressing auditory hallucinations and were 
diagnosed with schizophrenia (van der Gaag, van Oosterhout, Daalman, 
Somer, & Korrelboom, 2012). The outcomes, included in the Opoka and 
Lincoln (2017) review, were a small effect on depression and no effect 
on auditory hallucinations. 
Prior to conducting the current study, we worked with service users 
diagnosed with schizophrenia to adapt the original CoMeT protocol. 
Modifications included the potential to deliver the protocol through an 
increased number of sessions, and editing some of the written materials. 
The resultant protocol was termed ‘positive memory training’ (PoMeT) 
to reflect the predominant focus on a positive self-image within the 
treatment. 
1.2. The present investigation 
As detailed in our protocol (Steel et al., 2015), the primary hy-
pothesis to be tested was whether within patients who are diagnosed 
with schizophrenia and exhibit at least a mild level of depression, those 
who receive positive memory training will demonstrate a higher level 
of reduction in depressive symptoms than those who receive treatment 
as usual. The secondary hypotheses was that positive memory training 
will reduce the level of distressing psychotic symptoms. Further ana-
lyses will be conducted so as to assess for the role of self-esteem med-
iating any observed change in levels of depression within the treatment 
group. Also, self-esteem and depression will be assessed as potential 
mediators of change within the severity of psychotic symptoms within 
the treatment group. Health economic outcomes will be published se-
parately from the main clinical outcomes. 
2. Method 
2.1. Trial design 
This was a randomised, controlled, single-blind trial conducted in 
two UK centres: the Berkshire National Health Service (NHS) 
Foundation Trust and the Southern Health NHS Foundation Trust. The 
sites covered populations of about 0.8 and 1.2 million people respec-
tively. We sought referrals of patients aged 18–65 with a current DSM-V 
diagnosis of schizophrenia or schizo-affective disorder from both cen-
tres. The inclusion criteria were: exhibiting at least a mild level of de-
pression, defined as a score of 14 or over on the Beck Depression 
Inventory II (BDI-II; Beck, Steer, & Brown, 1996), no organic 
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impairment which was considered the primary diagnosis, able and 
willing to provide consent, do not exhibit a learning disability, and a 
sufficient understanding of spoken English to engage with assessments 
and the clinical intervention. 
The study was approved by the NHS Research Ethics Committee 
(reference 13/SC/0634) and the trial protocol has been published (Steel 
et al., 2015) and registered prospectively (ISRCTN99485756). No 
changes were made to the published trial protocol after the first ran-
domisation. 
2.2. Randomisation and masking 
Following eligibility and baseline assessment we randomly assigned 
(1:1) participants to either an intervention (PoMeT) or control (TAU) 
group using an online service (sealedenvelope). We stratified rando-
misation by site and by severity of depression (above and below a BDI-II 
score of 29, i.e. a severe level of depression) using randomised-per-
muted blocks of 4–6. Group allocation was revealed to the participant, 
trial manager and trial therapists whilst assessors were masked. The 
trial adhered to procedures to maintain separation between research 
staff who measured outcomes and clinical staff who delivered the in-
tervention. This included the use of separate offices, separate booking 
systems when seeing participants and separate agendas within team 
meetings. Where an allocation was revealed to an assessor during an 
assessment, masking was maintained through outcome data being ob-
tained via the recording of the assessment being rated by another as-
sessor. This occurred on 11 occasions (approximately 3% of the total 
number of assessments). 
2.3. Procedures 
The trial intervention (PoMeT) was delivered in up to 12 sessions 
over a period of 3-months, with 8 sessions or more being considered a 
full ‘dose’ of therapy. Sessions were delivered individually, lasted ap-
proximately 1 h and took place within an NHS clinic or in the partici-
pant's home. 
PoMeT is designed to enhance access to positive self-representations 
resulting in reduced levels of depression and increased self-esteem. It is 
based on a theoretical account of mood disorder (Brewin, 2006) which 
suggests that positive self-representations are relatively dormant within 
individuals suffering from depression, at least in part due to infrequent 
activation. The first stage of therapy involved the patient identifying 
their core negative self-representation, such as being “worthless”. 
Within the first session the therapist moved towards the identification 
of personality characteristics which were inconsistent with being 
“worthless”. Homework involved writing as many specific examples as 
possible within which the patient has demonstrated these character-
istics, e.g. being thanked for being a good friend. Subsequent sessions 
moved towards working with as many of these specific ‘positive 
memories’ as possible, through the use of imagery, posture and self- 
statements whilst ‘reliving’ these past positive events. Repeated re-
hearsal was aimed at maximising the extent to which the positive self- 
representations would be more easily activated in the ‘retrieval com-
petition’ with the negative self-representations. It was important that 
the meaning of the positive events provided a direct challenge to the 
originally identified negative self-representation. A major component of 
the intervention protocol was daily practice of positive self-re-
presentation recall in between weekly sessions. The final stages of the 
intervention involved the patient being trained to activate a positive 
self-representation at a time when an external environmental cue trig-
gered a negative self-representation. The intervention is manualised 
and highly structured. Whilst the original protocol adopted 8 sessions of 
1 h (Korrelboom, de Jong, et al., 2009), on the advice of a service-user 
focus group our study protocol allowed up to 12 sessions to enable some 
flexibility in the delivery. 
The intervention was delivered by three clinicians; a mental health 
nurse who was an accredited cognitive behavioural therapist, a coun-
selling psychologist and a clinical psychologist. Supervision was pro-
vided by team members (KK and MvdG) with relevant expertise both in 
the intervention and patient group. Sessions were recorded where the 
patient gave consent. Adherence to treatment protocol was monitored 
through the use of a measure specifically designed for the current trial 
and aimed to differentiate between the delivery of PoMeT and standard 
CBT or counselling. 
TAU was delivered by mental health professionals from within the 
NHS Trusts and was based on local protocols. All treatment was re-
corded as part of the amended Client Service Receipt Inventory 
(Beecham & Knapp, 2001) used for the collection of health and social 
care data and typically included medication and contact with psy-
chiatrists and community psychiatric nurses, while information on the 
PoMeT intervention was recorded as part of specific therapist diaries. 
2.4. Measures 
Assessments were conducted by graduate psychologists at baseline 
(prior to randomisation) at 3 months (end of treatment for those who 
received it) and 6 months and 9 months after baseline (i.e. follow-up 
assessments). 
The primary outcome was current level of depressed mood as 
measured by the BDI-II (Beck et al., 1996) at 3-month, 6-month and 9- 
months. Secondary outcome measures were self-esteem as measured by 
the Rosenberg Self- Esteem Scale (Rosenberg, 1965), psychotic symp-
toms measured by the Positive and Negative Syndrome Scale (PANSS;  
Kay, Opler, & Lindenmayer, 1987) and the Psychotic Symptom Rating 
Scale (PSYRATS; Haddock, McCarron, Tarrier, & Faragher, 1999), an-
xiety measured using the Generalised Anxiety Disorder Assessment 
(GAD7; Spitzer, Kroenke, Williams, & Lowe, 2006) and functioning 
measured using the Work and Social Adjustment Scale (WASAS; Mundt, 
Marks, Shear, & Gresit, 2002). Patient wellbeing was assessed using the 
Warwick-Edinburgh Mental Wellbeing Scale (WEMBS, Tennant, Hiller, 
Fishwick, Platyt, Jospeh, Weich et al., 2007). 
Patients’ health-related quality of life was measured by the EuroQol 
EQ-5D (EuroQol Group, 1990), while broader wellbeing was measured 
by the ICECAP-A (Al-Janabi, Flynn, & Coast, 2012) and OxCAP-MH 
(Simon et al., 2013) instruments. 
All measures were completed at baseline, 3-month and 9-month 
assessments. The 6-month assessment included only measures of de-
pression and health-related quality of life. 
All serious adverse events were documented throughout the trial 
and reported to the Data Monitoring and Ethics Committee, where the 
independent chair determined whether the event was attributed to the 
delivery of the intervention. 
2.5. Statistical analysis 
All analyses were carried out on an intention to treat principle. 
Sample size was estimated on the basis of 50 participants per group 
having 80% power to detect the PoMeT + TAU group presenting with a 
BDI-II score of 7 or more lower than the TAU group (SD = 10) at the 
2.5% level of significance (two-tailed). Outcome measures for the in-
tervention and treatment as usual (control) groups were compared 
using linear mixed-effects models. The dependent variables were the 
outcome measures at post-intervention and follow-up. Outcome mea-
sures at baseline, group membership and time were included as fixed 
explanatory variables. The models also included random effects for 
patients to allow for the correlation between post-intervention and 
follow-up outcome measures. Additionally, the models contained in-
teraction between time and group to test whether the effects of the 
intervention and usual treatment varied between post-intervention and 
follow-up time points. Standard diagnostic evaluations of model as-
sumptions were conducted to ensure valid inference. Uncertainty in the 
base case results was assessed using non-parametric methods and 
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extensive sensitivity analyses (Thanbane, Mbuagbaw, Zhang, Samaan, 
Marcucci, Ye et al., 2013). 
2.6. Mediation analysis 
Analyses were conducted so as to assess for the role of self-esteem 
mediating any observed change in levels of depression within the 
treatment group. Also, self-esteem and depression were assessed as 
potential mediators of change within the severity of psychotic symp-
toms within the treatment group. 
3. Results 
3.1. Sample characteristics 
In total 262 referrals were provided for the study of whom 119 gave 
consent and were assessed for eligibility using the BDI-II (see Fig. 1), 
and 100 were eligible and randomly assigned to either the PoMeT 
group (n = 49) or treatment as usual (n = 51). Fifty-three of the 100 
participants were recruited from SHFT whilst 47 were recruited from 
BHFT. 
As seen in Table 1, the majority of the sample were male, of white 
British ethic origin and unemployed. The most common psychiatric 
diagnosis was schizophrenia, with the majority having received at least 
one psychiatric admission to hospital during their lifetime. All but 5 
participants (all from the TAU group) were taking antipsychotic med-
ication, whereas 44 participants (19 from the POMET group, and 25 
from the TAU group) were not taking antidepressant medication (see  
Table 1). 
Of the 49 who were allocated to receive PoMeT, 40 (82%) received 
a full dose of between 8 and 12 sessions, whilst 5 (10%) attended be-
tween 4 and 7 sessions and 4 (8%) disengaged from the intervention 
within the first two sessions. There was one trial therapist based at 
SHFT who delivered PoMeT to all those allocated to receive it within 
that site (n = 26), as well as to 5 of the 23 allocated to received PoMeT 
within the BHFT site. The remaining 18 cases within the BHFT site were 
allocated to two trial therapists seeing 16 and 2 participants. A random 
recorded session from 20% of the treatment cases were assessed by an 
Fig. 1. Consort diagram.  
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independent expert in the intervention and all were rated as adherent to 
the treatment protocol. 
3.2. Outcome measures 
Compared with the TAU group, those who received the PoMeT in-
tervention showed a significant moderate effect of treatment on the 
primary outcome (depression) at 3 months (adjusted mean differ-
ence = 4.33; 95% CI = 0.38–8.23; p = 0.03; Cohen's d = 0.43). 
Although the gains were preserved in the experimental group, the effect 
reduced over time and was non-significant both at 6-months and 9- 
months (see Table 2). There were no other significant treatment effects 
on any of the secondary outcome measures (see Table 3). Whilst the 
outcome effect at 3 months for PSYRATS hallucinations was in the 
moderate range, the large confidence intervals indicate a non-sig-
nificant result. This outcome will be a product of the smaller sample 
size when only those who reported experiencing auditory hallucina-
tions as baseline were considered, i.e. n = 63. 
Overall, we recorded 22 serious adverse events (11 from the PoMeT 
group and 11 from the TAU group) with one death (TAU group) and no 
suicide attempts. None were associated with the delivery of the trial 
intervention. These events consisted of brief periods in medical hospital 
due to a variety of conditions (5 for PoMeT group and 6 for TAU group) 
and time spent in psychiatric hospital due to a period of symptom ex-
acerbation (7 for PoMeT group and 5 for TAU group). 
3.3. Mediation analysis 
Inference about mediation was based on the unstandardised indirect 
effect of treatment on outcome through the mediator (Hayes and 
Rockwood, 2017). Elucidating the role of self-esteem in mediating the 
treatment effect on depression at 3 months involved fitting two separate 
models each containing baseline measures of depression and self-es-
teem as covariates. The indirect effect of PoMeT on depression through 
self-esteem was not significantly different from zero (0.98; 95% CI 
-0.90-3.10). 
We also evaluated whether changes in depression and self-esteem 
mediated change within psychotic symptom (hallucination and delu-
sion) outcome scores at 3 months by estimating each mediator effect on 
outcome, adjusted for the other mediator. Indirect effects of PoMeT on 
hallucinations through depression (2.38; 95% CI -0.67-6.90) and 
through self-esteem (−0.40; 95% CI -3.07-1.91) were not significant. 
Also, the indirect effects of PoMeT on delusions through depression 
(1.14; 95% CI -0.54-2.90) and through self-esteem (−0.24; 95% CI 
-1.63-0.47) were not significant. 
4. Discussion 
Results partially support our primary hypothesis in that individuals 
who received positive memory training demonstrated a greater reduc-
tion in the symptoms of depression, at the end of treatment, than those 
who received treatment as usual. However, the level of change in de-
pression scores was below the seven-point difference that the study was 
designed to detect. Also, during the follow-up period, the control group 
also exhibit a symptom reduction and group differences are not main-
tained. The current moderate end of treatment effect size of 0.43 is 
comparable to that of 0.36 reported within the only meta-analysis of 
CBT for psychosis outcomes on mood (Wykes, Steel, Everitt, & Tarrier, 
2008). However, given the current trial was conducted with a high level 
of methodological rigor, the more meaningful comparison would be 
with the effect size of 0.08 which was reported for the equivalent high- 
quality trials within the same meta-analysis. Further, our outcomes 
were obtained within a 3-month treatment period. This is considerably 
shorter than the majority of trials reported within the meta-analysis and 
those trials which have contributed to the current UK government 
guidelines (NICE, 2009). It is of interest that the recent Sonmez et al. 
(2020) study adopted a generic CBT approach and did not report sig-
nificant effects at the end of treatment. Whereas, the current approach, 
along with that adopted by Freeman et al. (2014), are brief interven-
tions targeting specific mechanisms associated with the maintenance of 
depression. Both approaches also put an emphasis on developing po-
sitive thoughts and emotions, rather than negating a negative. How-
ever, positive memory training places more emphasis on training the 
activation of specific positive self-representations that Freeman et al. 
(2014), which worked with a wider range of positive thoughts and 
emotions. Both approaches produced a significant effect at the end of 
treatment which was not maintained at follow-up. Evidence would 
therefore suggest future interventions focus on targeting specific me-
chanisms associated with depression, generate positive thought and 
emotion, and are modified to maximise the potential for gains to be 
maintained. 
Our secondary hypothesis of a reduction in psychotic symptoms was 
not supported, and there were no significant effects on any other out-
come measures. The outcomes on psychotic symptoms are at odds with 
the Opoka et al. (2018) review. However, it is of note that the change in 
auditory hallucination scores indicated an end of treatment effect size 
of 0.46, which is in line with the outcome of the most recent meta- 
Table 1 
Baseline characteristics of the sample.       
PoMeT  
(n = 49) 
TAU  
(n = 51) 
Total  
(n = 100)  
Demographics 
Mean age in years (SD) 42.5 (9.9) 43.4 
(11.2) 
43.0 (10.6) 
Male (%) 69.4 80.4 75.0 
White (%) 91.8 88.2 90.0 
Age left formal education 16.4 (1.3) 16.5 (1.6) 16.4 (1.5) 
Currently Employed (%) 12.2 5.9 9.0 
Primary Diagnosis 
Schizophrenia 69.4 70.6 70.0 




83.7 82.4 83.0 
Mean number of prior Admissions 5.1 (7.1) 4.0 (5.3) 4.5 (6.2) 
Mean age at first contact with mental 
healthservicesChlorpromazine- 











Fluoxetine-equivalent dose of 







Primary outcome at baseline, 3-months, 6-months and 9-months.          
Unadjusted mean (SD) BDI-II Adjusted mean difference (SE) 95% CI Cohen's d p value 







4.33 (2.00) (0.38, 8.23) 0.43 0.03 
Month 6 21.2 (13.6) 22.9 (13.2) 2.27 (1.66) (-1.03, 5.58) 0.23 0.17 
Month 9 21.5 (14.0) 21.0 (12.6) 0.22 (2.01) (-3.76, 4.20) 0.02 0.91 
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analysis of CBT for hallucinations (van der Gaag, Valmaggia, & Smit, 
2014). Although not all of our sample reported experiencing hearing 
voices and therefore were not included in this section, resulting in re-
duced power for this analysis. Cost-effectiveness outcomes will be re-
ported separately. Further analyses did not reveal any mediation effects 
of self-esteem on change in depression, or on either of these variables 
mediating any change in psychotic symptoms. 
The increased mood levels obtained during the delivery of positive 
memory training were maintained at 6 and 9-month follow-ups. The 9- 
month assessment represents a no treatment follow-up duration of 
twice the length of the actual treatment itself, which is unusually ex-
tensive for a psychological treatment trial. However, the follow-up 
outcomes for PoMeT are non-significant, due to the symptom recovery 
exhibited within the treatment as usual group. The reduced levels of 
depression in our control group is at odds with the epidemiological data 
for co-morbid depression (Buckley et al., 2009), but is a common oc-
currence within clinical trials of psychological therapies. Participants 
were not recruited at a time of crisis, so regression to the mean would 
seem an unlikely explanation. One possibility is that participants ran-
domised to a treatment as usual condition receive an enhanced level of 
care, both during the trial intervention period and beyond, compared to 
that which would have occurred had the trial not existed. This may be 
through those involved in the participant's care becoming more alert to 
their psychological needs and providing, or facilitating access to, in-
creased clinical input. 
The most significant limitation of our study is that the comparison 
group did not control for therapist contact time or provide an active 
treatment. Therefore, we are limited in the confidence with which we 
can conclude that the significant treatment effect was due to the spe-
cific content of the positive memory training protocol. Our conclusions 
are based on what can be determined about the likely outcomes of the 
interventions that could have been chosen as an active control from the 
available literature. An ideal active control would have been generic 
CBT for psychosis. As has been discussed, a meta-analysis of outcomes 
on mood for high quality CBT for psychosis trials indicated an effect 
size of 0.08, considerably lower than that obtained in the current trial. 
Another limitation is that the study was only conducted in two NHS 
Trusts in the South of England, and by only three clinicians. Further 
work is required to confirm generalisability. 
The current study is the largest randomised controlled trial of a 
psychological therapy specifically targeting the treatment of depression 
in people diagnosed with schizophrenia. Positive memory training was 
feasible to deliver, demonstrated high levels of acceptability and there 
were no serious adverse effects associated with the intervention. Within 
our sample, patients exhibited a degree of natural recovery from de-
pression over time. However, the recovery was quicker for those who 
Table 3 
Secondary outcomes at baseline, 3-months and 9-months.         
Unadjusted mean (SD) Adjusted mean difference (95% CI) Cohen's d p value  








0.90 (−0.83, 2.64) 0.16 0.30 








−0.31 (−5.78, 5.16) −0.02 0.91 








−0.09 (−3.27, 3.19) −0.01 0.96 
Month 9 37.3 (10.0) 37.9 (10.3) 0.97 (4.21, 2.27) 0.12 0.56 







−0.52 (−2.28, 1.24) −0.09 0.56 
Month 9 17.6 (6.9) 17.1 (6.4) −0.32 (−2.36, 1.72) −0.05 0.75 







1.15 (−0.30, 2.59) 0.22 0.12 
Month 9 16.4 (5.0) 18.0 (4.7) 0.85 (−0.88, 2.58) 0.16 0.33 







5.51 (−1.07, 12.09) 0.46 0.10 








−0.79 (−3.79, 2.21) −0.11 0.60 








1.49 (−0.34, 3.32) 0.26 0.11 








−2.06 (−5.36, 1.23) −0.25 0.22 








−1.40 (−4.33, 1.52) −0.13 0.34 
Month 9 37.0 (11.1) 37.4 (11.8) 0.67 (−2.52, 3.87) 0.06 0.68 
RSES = Rosenberg Self-Esteem Scale. PANSS = Positive and Negative Symptom Scale. PSYRATS = Psychotic Symptom Rating Scales. GAD7 = Generalised Anxiety 
Disorder 7. WASAS = Work and Social Adjustment Scale. WEMWBS = Warwick-Edinburgh Mental Well-being Scale.  
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received positive memory training. This outcome is likely to be of value 
to service-users and may have an impact on relapse rate reduction, 
although larger studies are required to address this question. Overall, 
our results suggest that if low mood is the primary target within a 
psychological approach to this disorder, then positive memory training 
provides a briefer alternative to generic CBT for psychosis, and is likely 
to have a larger impact. The impact of PoMeT on quality of life and the 
cost-effectiveness of the intervention has been subject to a specific 
health economic analysis and will be reported separately. 
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